Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP4 | P15090 | 1/20 | 0.42 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.42 |
| ▸ | ALOX5AP | P20292 | 7/20 | 0.42 |
| ▸ | FEN1 | P39748 | 7/20 | 0.42 |
| ▸ | PGAM1 | P18669 | 1/20 | 0.41 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.41 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 3/20 | 0.38 |
| ▸ | HTR2C | P28335 | 3/20 | 0.38 |
| ▸ | MYC | P01106 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.37 |
| ▸ | GPR3 | P46089 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL776011 | 0.83 | NPSR1 (0.43) | PGAM1MYCPTPN1NFE2L2 | |
| SCHEMBL2006811 | 0.83 | PTPRC (0.43) | ALOX5APFEN1PGAM1 | |
| SCHEMBL1711745 | 0.83 | FABP4 (0.42) | FABP4FABP5ALOX5APFEN1PTGES2 | |
| SCHEMBL778696 | 0.81 | PGAM1 (0.46) | PGAM1P2RY4HTR2AHTR2CMYC | |
| SCHEMBL458284 | 0.79 | SMN1; SMN2 (0.48) | FABP4PGAM1MYC | |
| SCHEMBL780394 | 0.79 | ALDH1A1 (0.42) | FABP4FABP5NFE2L2 | |
| SCHEMBL28837581 | 0.77 | SMN1; SMN2 (0.46) | FABP4PGAM1MYC | |
| SCHEMBL778751 | 0.77 | PTGS2 (0.53) | ALOX5APFEN1HTR2CMYC | |
| SCHEMBL778996 | 0.76 | PTPN1 (0.46) | ALOX5APFEN1PGAM1PTGES2P2RY4 | |
| SCHEMBL19519153 | 0.76 | AKR1B1 (0.45) | HTR2AHTR2CMYCKCNH2NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2349990-B1 | ARYL-PHENYL-SULFONAMIDE-PHENYLENE COMPOUNDS AND THEIR USE | PIMCO 2664 LTD (GB) | 2018-05-02 | — | — | EP | disclosed |
| US-9608291-B2 | Non-aqueous liquid electrolyte and non-aqueous liquid electrolyte secondary battery | MITSUBISHI CHEMICAL CORPORATION (JP) | 2017-03-28 | — | — | US | disclosed |
| US-9343777-B2 | Non-aqueous liquid electrolyte and non-aqueous liquid electrolyte secondary battery | MITSUBISHI CHEMICAL CORPORATION (JP) | 2016-05-17 | — | — | US | disclosed |
| US-9252457-B2 | Non-aqueous liquid electrolyte and non-aqueous liquid electrolyte secondary battery | MITSUBISHI CHEMICAL CORPORATION (JP) | 2016-02-02 | — | — | US | disclosed |
| US-20150188192-A1 | NON-AQUEOUS LIQUID ELECTROLYTE AND NON-AQUEOUS LIQUID ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2015-07-02 | — | — | US | disclosed |
| US-20120177988-A1 | NON-AQUEOUS LIQUID ELECTROLYTE AND NON-AQUEOUS LIQUID ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2012-07-12 | — | — | US | disclosed |
| US-8207167-B2 | Aryl-phenyl-sulfonamide-phenylene compounds and their use | PIMCO 2664 LIMITED (GB) | 2012-06-26 | — | — | US | disclosed |
| US-20120070731-A1 | NON-AQUEOUS LIQUID ELECTROLYTE AND NON-AQUEOUS LIQUID ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2012-03-22 | — | — | US | disclosed |
| US-20110190302-A1 | Aryl-Phenyl-Sulfonamide-Phenylene Compounds and Their Use | PIMCO 2664 LIMITED (GB) | 2011-08-04 | — | — | US | disclosed |
| EP-2349990-A1 | ARYL-PHENYL-SULFONAMIDE-PHENYLENE COMPOUNDS AND THEIR USE | Pimco 2664 Limited (GB) | 2011-08-03 | — | — | EP | disclosed |
| WO-2010032010-A1 | ARYL-PHENYL-SULFONAMIDE-PHENYLENE COMPOUNDS AND THEIR USE | PIMCO 2664 LIMITED (GB) | 2010-03-25 | — | — | WO | disclosed |
| US-20090325065-A1 | NON-AQUEOUS LIQUID ELECTROLYTE AND NON-AQUEOUS LIQUID ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190302-A1 | Aryl-Phenyl-Sulfonamide-Phenylene Compounds and Their Use | SOST, PSAP, ARSA | FABP4 1014/4885FABP5 2168/4885ALOX5AP 603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.